News

08 Nov 2017

REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

Press release: REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
Read More >>

08 Nov 2017

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017
Read More >>

07 Nov 2017

Prof Stefan Przyborski to chair and speak at SMi Group’s 3D Cell Culture 2018 Conference

REPROCELL Europe Ltd's CSO Prof Stefan Przyborski to chair and speak at SMi Group’s 3D Cell Culture 2018 Conference
Read More >>

27 Sep 2017

Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017

REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017. The article is in the EPR’s section, Applied Research, Development and Production. It is co-authored by David Bunton at REPROCELL Europe, Marian McNeil at Stratified Medicine Scotland and Pamela Brankin at Aridhia.
Read More >>

1 2 3 4 >>

Biopta is attending Collaboration Nation on the 14th October following completion of a technology inspired feasibility study.

13/10/2015

Biopta will be presenting at Innovate UK’s Collaboration Nation event on the 14th October. This event is a showcase of the inspiring winners of Innovate UK’s recent Technology Inspired feasibility studies competition across four enabling technology areas that underpin future UK growth (Advanced materials; Biosciences; Electronics, sensors and photonics; and Information and communication technology (ICT)).

Biopta has been conducting a study, with the assistance of AstraZeneca,  to assess the feasibility of high content, phenotypic screening in fresh human tissue slices. Fresh tissue slices maintain the architecture and cellular interactions of native tissue and may therefore more accurately predict clinical responses. Multiple parameters can be assessed within each tissue slice using high content biology instrumentation and if applied early in the drug discovery process the potential exists to greatly improve the quality of hits and the lead optimisation process. Screening in fresh human tissues slices may also help to mitigate the risk of late stage clinical failure. Preliminary data shows that it is feasible to miniaturise a precision cut lung slice model from a 12 well  to a 96 well plate format. Tissue viability is maintained up to 24hrs and further work will be conducted to optimise the miniaturisation process and eventually expand to multiple tissue types.

Click here to watch the event live.

Live chat by BoldChat